Fig. 2

TQ and cisplatin combine to decrease tumor burden. BL/6 mice were injected with ID8-NGL cells. Thirty days after tumor cell injection, mice were randomized and treated with PBS vehicle (Veh), TQ (20 mg/kg thrice weekly), cisplatin (Cisp; 2 mg/kg weekly) or the TQ/cisplatin combination for 30 days and sacrificed. At sacrifice, a ascites fluid volume, b number of peritoneal implants and c mesenteric tumor mass were measured. Values are mean + SD for 5 mice per group; *p < 0.01 relative to vehicle; all p values determined were by Mann–Whitney test